{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T23:09:12Z","timestamp":1770505752118,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ijantimicag.2007.11.011","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T17:14:41Z","timestamp":1200503681000},"page":"235-239","source":"Crossref","is-referenced-by-count":16,"title":["Pharmacodynamics of doxycycline for chemoprophylaxis of Lyme disease: preliminary findings and possible implications for other antimicrobials"],"prefix":"10.1016","volume":"31","author":[{"given":"Jooyun","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary P.","family":"Wormser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2007.11.011_bib1","unstructured":"Centers for Disease Control and Prevention (CDC). Lyme disease\u2013United States, 2001\u20132002. MMWR Morb Mortal Wkly Rep 2004; 53:365\u20139."},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib2","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1056\/NEJMra021397","article-title":"How can we prevent Lyme disease?","volume":"348","author":"Hayes","year":"2003","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00508-005-0362-7","article-title":"Prevention of Lyme borreliosis","volume":"117","author":"Wormser","year":"2005","journal-title":"Wien Klin Wochenschr"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1056\/NEJM200107123450201","article-title":"Prophylaxis with single-dose doxycycline for the prevention of Lyme disease after an Ixodes scapularis tick bite","volume":"345","author":"Nadelman","year":"2001","journal-title":"New Engl J Med"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib5","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.1128\/AAC.48.7.2697-2699.2004","article-title":"Sustained-release formulation of doxycycline hyclate for prophylaxis of tick bite infection in a murine model of Lyme borreliosis","volume":"48","author":"Zeidner","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib6","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1086\/508667","article-title":"The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America","volume":"43","author":"Wormser","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib7","series-title":"39th Annual Meeting of the Infectious Diseases Society of America","article-title":"Magnitude of the 24h AUC\/MIC required for efficacy of doxycycline (DOXY) against Streptococcus pneumoniae (SP) in a murine thigh-infection model","author":"Christianson","year":"2001"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib8","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics\u2013pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/BF01780660","article-title":"In vitro susceptibility of thirty Borrelia strains from various sources against eight antimicrobial chemotherapeutics","volume":"24","author":"Baradaran-Dilmaghani","year":"1996","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib10","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1128\/AAC.37.8.1704","article-title":"Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi","volume":"37","author":"Dever","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s100960050005","article-title":"New colorimetric microdilution method for in vitro susceptibility testing of Borrelia burgdorferi against antimicrobial substances","volume":"19","author":"Hunfeld","year":"2000","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1128\/AAC.48.1.344-347.2004","article-title":"Comparison of in vitro activities of ketolides, macrolides, and an azalide against the spirochete Borrelia burgdorferi","volume":"48","author":"Hunfeld","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib13","first-page":"549","article-title":"Susceptibility of the Lyme disease spirochete to seven antimicrobial agents","volume":"57","author":"Johnson","year":"1984","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib14","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1128\/AAC.37.7.1444","article-title":"In vitro susceptibility of Borrelia burgdorferi to 11 antimicrobial agents","volume":"37","author":"Levin","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib15","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1128\/AAC.43.12.3030","article-title":"Comparative bacteriostatic and bactericidal activities of cefodizime against Borrelia burgdorferi sensu lato","volume":"43","author":"Murgia","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib16","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1128\/JCM.41.4.1791-1793.2003","article-title":"In vitro susceptibility testing of four antibiotics against Borrelia burgdorferi: a comparison of results for the three genospecies Borrelia afzelii, Borrelia garinii, and Borrelia burgdorferi sensu stricto","volume":"41","author":"Sicklinger","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib17","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF01975840","article-title":"Concentrations of azithromycin in human tonsillar tissue","volume":"10","author":"Foulds","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib18","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1007\/BF01975845","article-title":"Concentration of azithromycin in human prostatic tissue","volume":"10","author":"Foulds","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2007.11.011_bib19","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/25.suppl_A.73","article-title":"The pharmacokinetics of azithromycin in human serum and tissues","volume":"25","author":"Foulds","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/BF01975842","article-title":"High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose","volume":"10","author":"Morris","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib21","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1128\/AAC.31.12.1948","article-title":"Pharmacokinetic and in vivo studies with azithromycin (CP-62993), a new macrolide with an extended half-life and excellent tissue distribution","volume":"31","author":"Girard","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl. A","key":"10.1016\/j.ijantimicag.2007.11.011_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/jac\/25.suppl_A.49","article-title":"Pharmacokinetics of azithromycin in rats and dogs","volume":"25","author":"Shepard","year":"1990","journal-title":"J Antimicrob Chemother"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2007.11.011_bib23","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0924-8579(01)00410-1","article-title":"Advanced-generation macrolides: tissue-directed antibiotics","volume":"18","author":"Amsden","year":"2001","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1128\/AAC.33.3.277","article-title":"In vitro and in vivo uptake of azithromycin (CP-62993) by phagocytic cells: possible mechanism of delivery and release at sites of infection","volume":"33","author":"Gladue","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib25","first-page":"521","article-title":"Isolation and cultivation of Lyme disease spirochetes","volume":"57","author":"Barbour","year":"1984","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib26","series-title":"Pharmacokinetics","author":"Gibaldi","year":"1982"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000220439","article-title":"Distribution and excretion of doxycycline in man","volume":"11","author":"Fabre","year":"1966","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib28","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib29","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1128\/AAC.11.3.462","article-title":"Bioavailability of tetracycline and doxycycline in fasted and nonfasted subjects","volume":"11","author":"Welling","year":"1977","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib30","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1007\/BF01975844","article-title":"Gynaecological tissue levels of azithromycin","volume":"10","author":"Krohn","year":"1991","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib31","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1128\/AAC.48.3.809-814.2004","article-title":"Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin","volume":"48","author":"Sugie","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib32","series-title":"Expanding indications of the new macrolides, azalides and streptogramins","first-page":"22","article-title":"Postantibiotic effects and dosing of macrolides, azalides and streptogramins","author":"Craig","year":"1997"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib33","doi-asserted-by":"crossref","first-page":"785","DOI":"10.7326\/0003-4819-124-9-199605010-00002","article-title":"Azithromycin compared with amoxicillin in the treatment of erythema migrans. A double-blind, randomized, controlled trial","volume":"124","author":"Luft","year":"1996","journal-title":"Ann Int Med"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib34","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ijantimicag.2003.11.006","article-title":"Prevention of the selection of resistant Staphylococcus aureus by moxifloxacin plus doxycycline in an in vitro dynamic model: an additive effect of the combination","volume":"23","author":"Firsov","year":"2004","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2007.11.011_bib35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1128\/AAC.35.7.1413","article-title":"Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model","volume":"35","author":"Fantin","year":"1991","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907005845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857907005845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,7]],"date-time":"2019-05-07T00:32:43Z","timestamp":1557189163000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857907005845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0924857907005845"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2007.11.011","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}